首页 > 市场调查报告书 > 製药

疫苗基因治疗学和RNAi

自扩增RNA合成市场规模、份额和成长分析：按产品类型、技术、应用领域、给药途径、最终用户和地区划分－2026-2033年产业预测

市场调查报告书

商品编码

1964350

自扩增RNA合成市场规模、份额和成长分析：按产品类型、技术、应用领域、给药途径、最终用户和地区划分－2026-2033年产业预测

Self-amplifying RNA Synthesis Market Size, Share, and Growth Analysis, By Product Type (Premade saRNA, Enzymes & Reagents), By Technology, By Application Area, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年02月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2024年全球自扩增RNA合成市值为1.0643亿美元，预计将从2025年的1.2686亿美元成长到2033年的5.1707亿美元。预测期（2026-2033年）的复合年增长率预计为19.2%。

全球自扩增RNA合成市场专注于创新生产技术，这些技术能够使RNA分子在细胞内复製，从而显着降低疫苗和治疗药物的剂量需求和成本。这一转变正吸引生物技术公司和契约製造日益增长的兴趣，因为它有助于在突发公共卫生事件中提高药物取得和快速反应。在体外转录、奈米颗粒递送和监管理解等方面的进步推动下，市场发展已从早期学术研究阶段发展到早期临床试验阶段。生产的扩充性至关重要。自扩增技术减少了所需的RNA量，即使是小规模批量生产也能满足广泛的市场需求。人工智慧技术透过自动化设计和製造流程、序列优化、结果预测和参数优化来提高效率，缩短开发週期并最大限度地减少废弃物。这推动了产能和市场机会的成长。

全球自扩增RNA合成市场驱动因素

近年来，脂质奈米颗粒製剂、标靶递送配体和生产技术的进步显着提高了自扩增RNA构建体的稳定性、细胞内吸收率和组织靶向性。这些创新使得转化效率更高，治疗效果更佳，且所需剂量更小。这些改进的递送技术降低了生物屏障，提高了全身性和局部给药的实用性，促进了产业界和学术研究人员之间的投资与合作。这种合作环境反过来又加速了新产品候选药物的开发平臺，增强了市场信心，并推动了自扩增RNA合成解决方案在治疗药物研发中的广泛应用。

全球自扩增RNA合成市场面临的限制因素

自扩增RNA的合成流程复杂，涉及精细的生产、纯化和製剂製程。这些要求需要先进的技术专长和专业设施，这对旨在进入市场的中小型企业来说是一个挑战。生产的复杂性会导致研发週期延长、产量受限以及潜在的供应链瓶颈。此外，客製化的工艺验证和熟练人员的配备也构成了营运障碍，并增加了固定成本。因此，这些因素阻碍了新候选物质的快速生产，并限制了整体市场成长。

自扩增RNA合成市场的全球趋势

全球自扩增RNA合成市场正经历一场变革，其驱动力主要来自于递送平台的创新。随着研发人员不断提升自扩增RNA疗法的稳定性、细胞内摄取和标靶表达能力，市场对先进的脂质体配方、载体设计和偶联技术给予了高度关注，旨在增强组织特异性和给药便利性。这些突破将扩大市场的治疗应用范围，使其超越疫苗范畴，透过持续表达和低频给药，应用于慢性病和罕见疾病的治疗。此外，策略性投资和研究合作正在加速平台成熟，打造出各具特色的产品，这些产品在递送性能和以患者为中心的给药方案方面具有竞争优势。

北美洲
- 我们
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场公司采取的策略
近期市场趋势
企业市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 按细分市场进行企业市占率分析
- 2023-2025年营收年比比较

主要企业简介

Moderna, Inc.
BioNTech SE
CureVac AG
Ginkgo Bioworks, Inc.
Zymeworks Inc.
Imperial College London（Department of Chemical Engineering）
Aarhus University
GreenLight Biosciences, Inc.
Transgene SA
eTheRNA Immunotherapies
Medigen Vaccine Biologics Corp.
Vaxart, Inc.
Synlogic, Inc.
Tiba Biotech
Aibio Pharma
Acuitas Therapeutics
RiboBio Co., Ltd.
Codiak BioSciences, Inc.
iBio, Inc.
Egenesis, Inc.

结论与建议

简介目录

Product Code: SQMIG35H2418

Global Self-Amplifying Rna Synthesis Market size was valued at USD 106.43 Million in 2024 and is poised to grow from USD 126.86 Million in 2025 to USD 517.07 Million by 2033, growing at a CAGR of 19.2% during the forecast period (2026-2033).

The global self-amplifying RNA synthesis market focuses on innovative production technologies allowing RNA molecules to replicate within cells, significantly lowering vaccine and therapeutic dosage requirements and costs. This shift facilitates greater accessibility and quicker responses during health emergencies, drawing increased interest from biotech companies and contract manufacturers. Market development has evolved from early academic investigations to initial clinical trials, boosted by advancements in in vitro transcription, nanoparticle delivery, and regulatory familiarity. Manufacturing scalability is crucial, as self-amplification reduces the necessary RNA mass, enabling smaller production runs while meeting extensive demands. AI technology enhances efficiency by automating design and manufacturing processes, optimizing sequences, predicting outcomes, and refining parameters, thereby shortening development timelines and minimizing waste, thus propelling growth in both production capabilities and market opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Self-Amplifying Rna Synthesis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Self-Amplifying Rna Synthesis Market Segments Analysis

Global self-amplifying rna synthesis market is segmented by product type, technology, application area, route of administration, end user and region. Based on product type, the market is segmented into Premade saRNA, Enzymes & Reagents, Kits & Consumables and Other Related Products. Based on technology, the market is segmented into In Vitro Synthesis and In Vivo Synthesis. Based on application area, the market is segmented into Therapeutics Development and Biomedical Research. Based on route of administration, the market is segmented into Intramuscular (IM), Subcutaneous (SC), Intradermal (ID) and Intravenous (IV). Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations (CDMOs), Academic & Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Self-Amplifying Rna Synthesis Market

Recent advancements in lipid nanoparticle formulations, targeted delivery ligands, and manufacturing techniques have significantly enhanced the stability, cellular absorption, and tissue targeting of self-amplifying RNA constructs. These innovations lead to more effective translation and therapeutic effects while minimizing dosage requirements. By mitigating biological barriers, these delivery enhancements improve the viability of both systemic and localized applications, fostering increased investment and collaboration between industry and academic researchers. Consequently, this collaborative environment accelerates the progression of new product candidates through the development pipeline, bolstering market confidence and promoting wider adoption of self-amplifying RNA synthesis solutions among therapeutic developers.

Restraints in the Global Self-Amplifying Rna Synthesis Market

The synthesis of self-amplifying RNA is characterized by complex workflows that involve meticulous production, purification, and formulation processes. These requirements demand significant technical expertise and specialized facilities, which can create challenges for smaller companies aiming to enter the market. The intricate nature of manufacturing can extend development timelines and restrict throughput, leading to potential supply chain bottlenecks. Additionally, the necessity for customized process validation and the recruitment of skilled personnel contribute to higher operational barriers and fixed costs. Consequently, these factors hinder the rapid production of new candidates, ultimately restraining the overall growth of the market.

Market Trends of the Global Self-Amplifying Rna Synthesis Market

The Global Self-Amplifying RNA Synthesis market is experiencing a transformative shift driven by innovations in delivery platforms. As developers enhance stability, cellular uptake, and targeted expression of self-amplifying RNA therapeutics, there is a clear focus on advanced lipid formulations, vector engineering, and conjugation methods to improve tissue specificity and dosing convenience. These breakthroughs expand the market's therapeutic reach beyond vaccines, facilitating applications in chronic and rare diseases through sustained expression with lower administration frequency. Furthermore, strategic investments and research collaborations are fostering platform maturation, resulting in distinct product profiles that offer competitive advantages centered on delivery performance and patient-centric administration options.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Technology Analysis
Value Chain Analysis

Global Self-amplifying RNA Synthesis Market Size by Product Type & CAGR (2026-2033)

Market Overview
Premade saRNA
Enzymes & Reagents
Kits & Consumables
Other Related Products

Global Self-amplifying RNA Synthesis Market Size by Technology & CAGR (2026-2033)

Market Overview
In Vitro Synthesis
In Vivo Synthesis

Global Self-amplifying RNA Synthesis Market Size by Application Area & CAGR (2026-2033)

Market Overview
Therapeutics Development
- Infectious Diseases
- Oncology
- Gene & Protein Therapy
- Other Therapeutic Applications
Biomedical Research

Global Self-amplifying RNA Synthesis Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intramuscular (IM)
Subcutaneous (SC)
Intradermal (ID)
Intravenous (IV)

Global Self-amplifying RNA Synthesis Market Size by End User & CAGR (2026-2033)

Market Overview
Pharmaceutical & Biotechnology Companies
Contract Development & Manufacturing Organizations (CDMOs)
Academic & Research Institutes
Others

Global Self-amplifying RNA Synthesis Market Size & CAGR (2026-2033)

North America (Product Type, Technology, Application Area, Route of Administration, End User)
- US
- Canada
Europe (Product Type, Technology, Application Area, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product Type, Technology, Application Area, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product Type, Technology, Application Area, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Product Type, Technology, Application Area, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Moderna, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CureVac AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ginkgo Bioworks, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Imperial College London (Department of Chemical Engineering)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aarhus University
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GreenLight Biosciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Transgene SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
eTheRNA Immunotherapies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medigen Vaccine Biologics Corp.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxart, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Synlogic, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tiba Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aibio Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acuitas Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RiboBio Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Codiak BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
iBio, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Egenesis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments